01 1Patheon Italia S.p.A.
02 1ScinoPharm Taiwan Ltd.
01 1Delafloxacin Meglumine
02 1delafloxacin meglumine
01 1Taiwan
02 1U.S.A
NDC Package Code : 68225-099
Start Marketing Date : 2017-06-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER, FOR SOLUTION (300mg/10.5mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 65129-2211
Start Marketing Date : 2016-11-25
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
A Delafloxacin Meglumine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Delafloxacin Meglumine, including repackagers and relabelers. The FDA regulates Delafloxacin Meglumine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Delafloxacin Meglumine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Delafloxacin Meglumine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Delafloxacin Meglumine supplier is an individual or a company that provides Delafloxacin Meglumine active pharmaceutical ingredient (API) or Delafloxacin Meglumine finished formulations upon request. The Delafloxacin Meglumine suppliers may include Delafloxacin Meglumine API manufacturers, exporters, distributors and traders.
click here to find a list of Delafloxacin Meglumine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Delafloxacin Meglumine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Delafloxacin Meglumine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Delafloxacin Meglumine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Delafloxacin Meglumine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Delafloxacin Meglumine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Delafloxacin Meglumine suppliers with NDC on PharmaCompass.
We have 2 companies offering Delafloxacin Meglumine
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
